-$0.89 EPS Expected for Cellectis SA (NASDAQ:CLLS) This Quarter
Brokerages expect Cellectis SA (NASDAQ:CLLS) to announce earnings of ($0.89) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Cellectis’ earnings. The lowest EPS estimate is ($0.97) and the highest is ($0.81). Cellectis posted earnings per share of ($0.54) in the same quarter last year, which would indicate a negative year over year growth rate of 64.8%. The company is scheduled to issue its next quarterly earnings results on Tuesday, November 12th.
According to Zacks, analysts expect that Cellectis will report full-year earnings of ($2.90) per share for the current year, with EPS estimates ranging from ($3.08) to ($2.71). For the next fiscal year, analysts anticipate that the business will post earnings of ($3.15) per share, with EPS estimates ranging from ($3.95) to ($2.61). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Cellectis.
Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.18). Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%. The business had revenue of $2.93 million during the quarter, compared to the consensus estimate of $3.45 million.
Cellectis stock traded up $0.07 during midday trading on Friday, hitting $12.67. The company’s stock had a trading volume of 91,438 shares, compared to its average volume of 121,127. The company has a quick ratio of 8.46, a current ratio of 8.47 and a debt-to-equity ratio of 0.11. The stock’s 50-day moving average price is $13.08 and its 200-day moving average price is $16.53. Cellectis has a 12 month low of $11.53 and a 12 month high of $29.40. The company has a market capitalization of $527.14 million, a PE ratio of -6.56 and a beta of 1.76.
A number of institutional investors and hedge funds have recently modified their holdings of CLLS. Nikko Asset Management Americas Inc. grew its stake in Cellectis by 48.9% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,224,334 shares of the biotechnology company’s stock valued at $19,100,000 after acquiring an additional 401,888 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Cellectis by 48.1% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,210,019 shares of the biotechnology company’s stock valued at $18,876,000 after buying an additional 392,841 shares during the last quarter. ARK Investment Management LLC lifted its holdings in shares of Cellectis by 18.1% during the 2nd quarter. ARK Investment Management LLC now owns 1,103,186 shares of the biotechnology company’s stock valued at $17,210,000 after buying an additional 169,110 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Cellectis by 56.6% during the 2nd quarter. Morgan Stanley now owns 494,775 shares of the biotechnology company’s stock valued at $7,719,000 after buying an additional 178,865 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Cellectis by 66.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 142,500 shares of the biotechnology company’s stock valued at $2,223,000 after buying an additional 57,100 shares during the last quarter. 32.30% of the stock is currently owned by hedge funds and other institutional investors.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Further Reading: What is an inverted yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.